Caption Management LLC Has $1.39 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Caption Management LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 24.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,007 shares of the company’s stock after selling 20,693 shares during the quarter. Caption Management LLC’s holdings in Kenvue were worth $1,388,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in Kenvue during the 4th quarter valued at $521,348,000. Franklin Resources Inc. increased its position in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock valued at $5,249,665,000 after acquiring an additional 8,211,748 shares in the last quarter. Finally, Boston Partners boosted its stake in Kenvue by 36.9% during the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock valued at $503,145,000 after purchasing an additional 6,366,097 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE:KVUE opened at $23.58 on Wednesday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The business has a fifty day simple moving average of $23.11 and a two-hundred day simple moving average of $22.54. The company has a market capitalization of $45.23 billion, a P/E ratio of 44.48, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is 154.72%.

Analyst Ratings Changes

Several analysts have recently commented on the company. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Citigroup increased their price target on Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a research report on Monday, April 14th. Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.